Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Dec. 17 Quick Takes: Ipsen, Genfit advancing former NASH candidate in PBC

Plus: ALS play Amylyx seeking NASDAQ listing and updates from Novartis, Pfizer-BioNTech, IN8bio and more

December 18, 2021 2:31 AM UTC

A year and a half after PPARα and PPARδ agonist elafibranor missed the primary endpoint in a Phase III study to treat non-alcoholic steatohepatitis, Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) has chosen Ipsen Group (Euronext:IPN; Pink:IPSEY) as its partner to advance the program to treat primary biliary cholangitis. Ahead of top-line data due in 1Q23 from the Phase III ELATIVE trial in PBC, Ipsen paid €120 million for a global license to the product and acquired an 8% stake in Genfit for €28 million; Genfit is eligible for a further €360 million in milestones, plus royalties. The treatment has breakthrough therapy designation from FDA, and orphan drug designation in the U.S. and EU.

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) submitted an sBLA for their Comirnaty vaccine in adolescents aged 12-15 years. FDA authorized the emergency use of Comirnaty in this patient population on May 10. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article